AxoSim Empowers Advancements in Human Neuroscience
AxoSim empowers advancements in human neuroscience by partnering with leading pharmaceutical and research institutions to facilitate therapeutic breakthroughs in the world’s most devastating neurodegenerative diseases.
The NerveSim® platform is the only in vitro model with Schwann cell myelination and human-relevant electrophysiological and structural data metrics, unlocking a powerful tool for human translation.
The BrainSim® platform is being developed to upend the way drugs are screened for myelin-related diseases of the CNS, such as multiple sclerosis and leukodystrophies.
With innovative drug discovery tools, AxoSim offers clinically-relevant data to select better lead candidates with functional, phenotypically accurate assays. AxoSim enables its partners to move safe and effective candidates toward the clinic faster than it has been done before.
Brands: AxoSim empowers advancements in human neuroscience by partnering with leading pharmaceutical and research institutions to facilitate therapeutic breakthroughs in the world’s most devastating neurodegenerative diseases.